Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
C3JyMRuqjUepL5sV
